<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994704</url>
  </required_header>
  <id_info>
    <org_study_id>3-2021-0216</org_study_id>
    <nct_id>NCT04994704</nct_id>
  </id_info>
  <brief_title>Comparison of Postoperative QoR-15 Scores Between Propofol and Remimazolam</brief_title>
  <official_title>Comparison of Postoperative Quality of Recovery (QoR)-15 Scores According to the Use of Anesthetics (Propofol vs. Remimazolam) During Total Intravenous Anesthesia in the Spine Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Remimazolam is a ultra-short-acting benzodiazepine, and unlike conventional benzodiazepine&#xD;
      drugs, it is rapidly metabolized in plasma and not accumulates in the body for long periods&#xD;
      of infusion or even with high dose administration. In addition, it has no injection pain and&#xD;
      infusion syndrome compared with propofol. In particular, there is no study to investigate&#xD;
      overall postoperative functional recovery via QoR-15 in patients receiving TIVA using&#xD;
      remimazolam. Therefore, rhe purpose of the study is to compare poetoperative quality of&#xD;
      recovery (QoR)-15 scores according to the use of anesthetics for total intravenous anesthesia&#xD;
      in the cervical spine surgery with intraoperative neurophysiological monitoring.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">August 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 4, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference of QoR-15 scores between two groups (propofol vs. remimazolam)</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>The difference of scores in the Quality of Recovery (QoR)-15 survey.Minimum value: 0, Maximum value: 150, higher scores means better.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Patients Undergoing Spine Surgery</condition>
  <arm_group>
    <arm_group_label>Propofol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol based total intravenous anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remimazolam group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam based total intravenous anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propfol group</intervention_name>
    <description>Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil under target controlled infusion (TCI) model.</description>
    <arm_group_label>Propofol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam group</intervention_name>
    <description>Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h for induction, and maintained at 0.5-1.5 mg/kg/h and remifentanil under TCI model.</description>
    <arm_group_label>Remimazolam group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients who aged 20-70 years with ASA-PS 1-3,&#xD;
&#xD;
          -  diagnosed of ossification of the posterior longitudinal ligament or cervical&#xD;
             spondylotic myelopathy&#xD;
&#xD;
          -  intraoperative neurophysiological monitoring.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tolerance or hypersensitivity to benzodiazepine or propofol&#xD;
&#xD;
          -  Dependence or addiction to psychotropic drugs or alcohol&#xD;
&#xD;
          -  Pregnant women, subjects who lack the ability to make decisions and susceptible to&#xD;
             voluntary participation decisions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dong Woo Han</last_name>
    <phone>82-2-2019-2740</phone>
    <email>HANESTH@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>GangnamSeverance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Woo Han</last_name>
      <phone>82-2-2019-2740</phone>
      <email>HANESTH@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Dong Woo Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

